These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15326317)

  • 21. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylphenidate: its pharmacology and uses.
    Challman TD; Lipsky JJ
    Mayo Clin Proc; 2000 Jul; 75(7):711-21. PubMed ID: 10907387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transdermal methylphenidate (Daytrana) for ADHD.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
    [No Abstract]   [Full Text] [Related]  

  • 25. The neurology of attention deficit/hyperactivity disorder.
    Curatolo P
    Brain Dev; 2005 Dec; 27(8):541-3. PubMed ID: 16310587
    [No Abstract]   [Full Text] [Related]  

  • 26. Thinking differently. Brain scans give new hope for diagnosing ADHD.
    Rogers A
    Newsweek; 1998 Dec; 132(23):60. PubMed ID: 10345222
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.
    Ozdag MF; Yorbik O; Ulas UH; Hamamcioglu K; Vural O
    Int J Pediatr Otorhinolaryngol; 2004 Oct; 68(10):1267-72. PubMed ID: 15364497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
    Strawn MN
    J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
    [No Abstract]   [Full Text] [Related]  

  • 29. The relationship between regional cerebral blood flow and response to methylphenidate in children with attention-deficit hyperactivity disorder: comparison between non-responders to methylphenidate and responders.
    Cho SC; Hwang JW; Kim BN; Lee HY; Kim HW; Lee JS; Shin MS; Lee DS
    J Psychiatr Res; 2007 Sep; 41(6):459-65. PubMed ID: 16839567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Methylphenidate. A possibility for rare hyperactive children].
    Rev Infirm; 2004 Sep; (103):39-40. PubMed ID: 15517803
    [No Abstract]   [Full Text] [Related]  

  • 31. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ADHD and the rise in stimulant use among children.
    Mayes R; Bagwell C; Erkulwater J
    Harv Rev Psychiatry; 2008; 16(3):151-66. PubMed ID: 18569037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of methylphenidate on Internet video game play in children with attention-deficit/hyperactivity disorder.
    Han DH; Lee YS; Na C; Ahn JY; Chung US; Daniels MA; Haws CA; Renshaw PF
    Compr Psychiatry; 2009; 50(3):251-6. PubMed ID: 19374970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.
    Fone KC; Nutt DJ
    Curr Opin Pharmacol; 2005 Feb; 5(1):87-93. PubMed ID: 15661631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attention deficit/hyperactivity disorder: a review and update.
    Cormier E
    J Pediatr Nurs; 2008 Oct; 23(5):345-57. PubMed ID: 18804015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
    Işeri E; Kiliç BG; Senol S; Karabacak NI
    Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
    Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
    Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

  • 40. Functional MRI in attention-deficit hyperactivity disorder: evidence for hypofrontality.
    Zang YF; Jin Z; Weng XC; Zhang L; Zeng YW; Yang L; Wang YF; Seidman LJ; Faraone SV
    Brain Dev; 2005 Dec; 27(8):544-50. PubMed ID: 15876503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.